The associations among co-morbidity, cardiac geometries and mechanics in hospitalized heart failure with or without preserved ejection fraction

References

• Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240–327.
   PubMed Web of Science ®Google Scholar
• Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. J Am Coll Cardiol 1989;14:564–70.
   PubMed Web of Science ®Google Scholar
• Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260–9.
   PubMed Web of Science ®Google Scholar
• Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251–9.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Zhao X, Heidenreich PA, et al. Get With the Guidelines Scientific Advisory Committee and Investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: Prevalence, therapies, and outcomes. Circulation 2012;126:65–75.
   Google Scholar
• Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac co-morbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012;59:998–1005.
   PubMed Web of Science ®Google Scholar
• Mohammed SF, Borlaug BA, Roger VL, et al. Co-morbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: A community-based study. Circ Heart Fail 2012;5:710–9.
   PubMed Web of Science ®Google Scholar
• Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Co-morbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263–71.
   PubMed Web of Science ®Google Scholar
• Cho GY, Marwick TH, Kim HS, et al. Global 2-dimensional strain as a new prognosticator in patients with heart failure. J Am Coll Cardiol 2009;54:618–2
   PubMed Web of Science ®Google Scholar
• Nahum J, Bensaid A, Dussault C, et al. Impact of longitudinal myocardial deformation on the prognosis of chronic heart failure patients. Circ Cardiovasc Imaging 2010;3:249–56
   PubMed Web of Science ®Google Scholar
• Mignot A, Donal E, Zaroui A, et al. Global longitudinal strain as a major predictor of cardiac events in patients with depressed left ventricular function: A multicenter study. J Am Soc Echocardiogr 2010;23:1019–24.
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB, et al. Recommendation for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiograpy. J Am Soc Echocardiogr 2005;18:1440–1463.
   Google Scholar
• Liao ZY, Peng MC, Yun CH, et al. Relation of carotid artery diameter with cardiac geometry and mechanics in heart failure with preserved ejection fraction. J Am Heart Assoc 2012;1:e003053.
   PubMed Web of Science ®Google Scholar
• Selvaraj S, Aguilar FG, Martinez EE, et al. Association of co-morbidity burden with abnormal cardiac mechanics: Findings from the HyperGEN study. J Am Heart Assoc 2014;3:e000631.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1–266
   PubMed Web of Science ®Google Scholar
• Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949;37:161–86
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial ischemia. Circulation 2007; 116:2634–53
   Google Scholar
• Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: Comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging 2009;2:356–364.
   PubMed Web of Science ®Google Scholar
• Yingchoncharoen T, Gibby C, Rodriguez LL, et al. Association of myocardial deformation with outcome in asymptomatic aortic stenosis with normal ejection fraction. Circ Cardiovasc Imaging 2012;5:719–725.
   PubMed Web of Science ®Google Scholar
• Borbély A, van der Velden J, Papp Z, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005;111:774–81.
   PubMed Web of Science ®Google Scholar
• Hung CL, Verma A, Uno H, et al. VALIANT investigators. Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol 2010;56:1812–22.
   Google Scholar
• Kouzu H, Yuda S, Muranaka A, et al. Left ventricular hypertrophy causes different changes in longitudinal, radial, and circumferential mechanics in patients with hypertension: A two-dimensional speckle tracking study. J Am Soc Echocardiogr 2011;24:192–9.
   PubMed Web of Science ®Google Scholar
• Wang J, Khoury DS, Yue Y, et al. Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure. Eur Heart J 2008;29:1283–1289.
   PubMed Web of Science ®Google Scholar
• Zile MR, Desantis SM, Baicu CF, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011;4:246–56.
   PubMed Web of Science ®Google Scholar
• Sengupta PP, Krishnamoorthy VK, Korinek J, et al. Left Ventricular Form and Function Revisited: Applied Translational Science to Cardiovascular Ultrasound Imaging. J Am Soc Echocardiogr 2007;20:539–51.
   PubMed Web of Science ®Google Scholar
• Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. NEngl J Med 1990;322:1561–1566.
   PubMed Web of Science ®Google Scholar
• Ho JE, Lyass A, Lee DS, et al. Predictors of newonsetheart failure: Differences in preserved versus reduced ejection fraction. Circ HeartFail 2013;6:279–286.
   PubMed Web of Science ®Google Scholar
• Marechaux S, Six-Carpentier MM, Bouabdallaoui N, et al. Prognostic importance of co-morbidities in heart failure with preserved left ventricular ejection fraction. Heart Vessels 2011;26:313–320.
   PubMed Web of Science ®Google Scholar
• Henkel DM, Redfield MM, Weston SA, et al. Death in heart failure: A community perspective. Circ Heart Fail 2008;1:91–7.
   PubMed Web of Science ®Google Scholar
• González A, Ravassa S, Beaumont J, et al. New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol 2011;58:1833–43.
   PubMed Web of Science ®Google Scholar
• Van Heerebeek L, Hamdani N, Falcão-Pires I, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 2012;126:830–9.
   PubMed Web of Science ®Google Scholar
• Falcão-Pires I, Hamdani N, Borbély A, et al. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation 2011;124:1151–9.
   PubMed Web of Science ®Google Scholar
• Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214–22.
   PubMed Web of Science ®Google Scholar
• Calderone A, Thaik CM, Takahashi N, et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998;101:812–8.
   PubMed Web of Science ®Google Scholar